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Abstract
Background: The UK Clinical Research Collaboration (UKCRC) registered Clinical Trials Units (CTUs) Network aims to
support high-quality, efficient and sustainable clinical trials research in the UK. To better understand the challenges
in efficient trial conduct, and to help prioritise tackling these challenges, we surveyed CTU staff. The aim was to identify
important inefficiencies during two key stages of the trial conduct life cycle: (i) from grant award to first participant, (ii)
from first participant to reporting of final results.
Methods: Respondents were asked to list their top three inefficiencies from grant award to recruitment of the first
participant, and from recruitment of the first participant to publication of results. Free text space allowed respondents
to explain why they thought these were important. The survey was constructed using SurveyMonkey and circulated to
the 45 registered CTUs in May 2013. Respondents were asked to name their unit and job title, but were otherwise
anonymous. Free-text responses were coded into broad categories.
Results: There were 43 respondents from 25 CTUs. The top inefficiency between grant award and recruitment of first
participant was reported as obtaining research and development (R&D) approvals by 23 respondents (53%), contracts
by 22 (51%), and other approvals by 13 (30%). The top inefficiency from recruitment of first participant to publication of
results was failure to meet recruitment targets, reported by 19 (44%) respondents. A common comment was that this
reflected overoptimistic or inaccurate estimates of recruitment at site. Data management, including case report form
design and delays in resolving data queries with sites, was reported as an important inefficiency by 11 (26%) respondents,
and preparation and submission for publication by 9 (21%).
Conclusions: Recommendations for improving the efficiency of trial conduct within the CTUs network include: further
reducing unnecessary bureaucracy in approvals and contracting; improving training for site staff; realistic recruitment
targets and appropriate feasibility; developing training across the network; improving the working relationships between
chief investigators and units; encouraging funders to release sufficient funding to allow prompt recruitment of trial staff; and
encouraging more research into how to improve the efficiency and quality of trial conduct.
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Background
Randomised trials are the gold standard for evaluating the
effects of interventions to improve health and wellbeing.
Trials addressing important health care questions are often
large multicentre studies, which are complex, expensive
multidisciplinary projects. Inefficiencies in the conduct of
trials may lead to wasted resources, to an extension of the
trial or, in extreme circumstances, to the trial failing to
complete or to answer the research question [1, 2].
The UK Clinical Research Collaboration (UKCRC)
registered Clinical Trials Units (CTUs) Network aims to
support high-quality, efficient, effective and sustainable
clinical trials research in the UK (http://www.ukcrc.org/
research-infrastructure/clinical-trials-units/). Currently
the network includes 50 CTUs, and these units primarily
conduct multicentre randomised trials. Since 2012, the
network has developed a work programme to support
members with information, guidance and representation
relevant to high-quality trial conduct. The Efficient Trial
Conduct subgroup of this work programme aimed to
explore new approaches and systems to improve trial
conduct and share good practice. To better understand
the challenges facing CTUs in conducting trials
efficiently, and to help prioritise its work, the Efficient
Trial Conduct subgroup surveyed staff working within
the registered CTUs about their views of the inefficiencies
in trial conduct.
The aim of this survey was to identify important in-
efficiencies during two key stages of the trial conduct
life cycle: (i) from grant award to first participant and
(ii) from first participant to reporting of final results.
Methods
The survey was developed by the Efficient Trial Conduct
subgroup of the registered CTUs work programme
(http://www.ukcrc.org/research-infrastructure/clinical-tri
als-units/). Respondents were asked to list their top
three inefficiencies from grant award to recruitment of
the first participant, and their top three inefficiencies
from recruitment of the first participant to publication
of results. There was additional free text space for
respondents to explain why they thought these were
important, if they wished. The survey was simple and
easy to complete, and we wanted to seek responses from
a wide range of job roles within the CTUs.
The survey was constructed online using SurveyMonkey.
A link to the survey was circulated in May 2013 to 45
registered CTUs (the number of units registered at that
time) using the email distribution lists for quality assur-
ance, information systems, statistics, trial managers and
pharmacovigilance. An email reminder was sent to all dis-
tribution lists after two weeks. Responses were received up
to 1 July 2013. Respondents were asked the name of their
CTU and their job title, but all responses were otherwise
anonymous. Free-text responses were coded into broad
categories.
Results
Overall, there were 43 respondents from 25 registered
CTUs. Multiple responses from different respondents
within the same CTU were included in the analysis: 13
units returned a single response, six submitted two
responses, two submitted three responses and two units
submitted five. Responses were received from units
across the four nations (England, Wales, Scotland and
Northern Ireland). One third of the respondents
reported their job title as within trial management, and
a fifth reported that they were CTU directors or in
senior management (Table 1).
Responses to question: ‘Between grant award and
recruitment of the first participant, what do you think are
the top three inefficiencies in trial conduct?’
Delays in obtaining research and development (R&D)
permissions and approvals were reported as the top inef-
ficiency by 23 respondents (53%); contracts by 22 (51%),
and other approvals by 13 (30%) (Fig. 1). Many of those
who reported R&D approvals as an inefficiency did not
explain why they thought this was important. Others
commented on the lack of change, and need for more
consistency:
No one believes it’s [R&D approvals] getting better – the
trusts are clearly gaming it by starting and stopping the
clock when they feel like it.
R&D’s individual requirements for what should be a
standardised process for R&D approval
The reported inefficiencies associated with contracts
included all types of contract: between the funder and
sponsor, between the sponsor and site or other
Table 1 Job titles for respondents
n = 43
Trial management (trial manager or coordinator) 14 33%
Director or senior management 8 19%
Research or programme manager 6 14%
Statistician 5 12%
Quality assurance 3 7%
IT or programmer 2 5%
Othera 5 12%
aProfessor or associate professor (n = 2), research fellow (n = 2), data
manager (n = 1)
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subcontractor, and with suppliers of the investigational
medicinal product.
Recruitment of staff to work on the trial was
reported as an inefficiency between grant award and
recruitment of the first participant by 11 (26%)
respondents. Largely, this seemed to be due to delays
in recruiting staff to work on the trial, although
sometimes it was not clear from these comments
whether this was staff in the unit or staff at sites. For
some units, funders not releasing the grant until
ethics approval had been secured was a significant
problem contributing to delays and inefficiency:
Issue when no core funding is in place to provide
some core staff who can start projects before the
trial-specific coordinators or trial managers are in
post, funded by the actual grant.
…the need for seedcorn funding to do tasks every study
requires. Clearly, seedcorn funding is better than having
to subsidise the activity from another project budget or
CTU support funding, but the idea that doing the
pre-ethics work should be subject to a separate
application is insane.
The same number of respondents noted that study
design and document development was inefficient. This
was commonly noted as developing and testing the case
report form (or electronic case report form), but also
included agreeing the protocol. Comments included:
Getting the investigators to decide the real detail of
exactly what they are doing.
Design of a robust case report form with adequate PI
[principal investigator] or nurse input.
Other reported inefficiencies included selection of sites
to participate in the trial, poor feasibility and piloting of
the trial at sites, and lack of adequate site training.
Typical comments were:
Poor assessment of feasibility by participating sites
(including potential evaluable patients).
Robust feasibility of deliverability.
Site initiation and training can be difficult as often
site staff are not available or are lacking GCP [good
clinical practice] training, which causes delays.
Responses to question: ‘From recruitment of the first
patient to publication of the trial results, what do you think
are the top three inefficiencies in trial conduct?’
The clear front-runner as the top inefficiency for this
section was ‘recruitment targets not met or overesti-
mation of predicted recruitment’, reported by 19 (44%)
respondents (Fig. 2). A common comment was that this
failure to meet recruitment targets reflected overopti-
mistic or inaccurate estimates of recruitment at site:
Sites wildly over-estimating suitable patient
availability.
Failure to recruit – often because eligibility criteria are
too tight and have to be widened.
Inaccurate estimations of likely number of eligible
patients per site.
Fig. 1 Inefficiencies between grant award and recruitment of first participant. CLRN, comprehensive local research network; IMP, investigational
medicinal product; IT, information technology; R&D, research and development
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Out-of-hours recruitment was also noted as an issue
for some trials:
… we work in emergency care trials and having 24/7
screening is paramount to success as patients can
come in at any time of day. Often sites are reliant on
a research nurse who is only available during office
hours. We have also had a number of times when we
have had to suspend sites who could not recruit patients
when no research nurse was in place (moved jobs) and it
may have taken 8–9 months to replace the nurse.
Data collection, including case report form design, was
reported as an important inefficiency by 11 (26%)
respondents, and preparation and submission for
publication by 9 (21%). Many of the issues noted with
data management related to delays in resolving data
queries with sites:
Timely data flow (related to site staff availability or
turnover).
Final clean dataset for analysis: data queries are not
resolved in a timely manner from sites.
For preparation and submission for publication,
several respondents commented that delays were due to
this often taking place after the end of the grant, when
key staff might have left the project:
Time and resources allocated to produce publication
(which is after grant end).
One comment was that negative findings might not
get published at all:
Publication bias – negative findings not published.
Inefficiencies in data management may contribute to
delays or inefficiencies in analysis and preparing results
for publication. One respondent reported how recognis-
ing this and improving the efficiency of data manage-
ment improved efficiency in preparing the final report:
Obviously, if you fail to plan ahead – you delay the
analysis and give less time for the report writing. Glad
to be blaming ourselves rather than someone else for
this one. We’ve realised that we can cut down the time
for data cleaning after follow-up is complete – to allow
speedy transfer of data to analysts – if we step up the
process of query resolution from 6 months before the
last participant’s last visit and get statisticians, health
economists and DM [data manager] looking at blinded
sample data to anticipate where the problems will be
early. We’ve put a lot of work into trying to make this
bit of the trial more efficient recently. The CI [chief
investigator] sometimes gets in the way, but mostly
they’re pleased and impressed that we’re thinking
ahead like that.
Site set-up and implementing ethics approval amend-
ments were reported as a top inefficiency by a fifth of
respondents (8, 19%). For ethics amendments, the issues
included time taken to secure amendments, and delays
in R&D to implement the amendment at sites.
Site selection and resources at sites were noted as
inefficiencies by several respondents:
Clinicians not having time or adequate support.
Lack of research nurse time to identify patients.
Poor engagement of the key clinical team, both chief
investigators and at sites, was also reported as an
inefficiency:
Fig. 2 Inefficiencies between recruitment of first participant and publication of trial results. CRF, case report form; PIL, participant
information leaflet
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Minimal communication between clinicians, trial
managers and statisticians during trial conduct.
Chief investigators not allocating sufficient time and
focus on trial.
Lost motivation from clinical staff.
Various aspects of project planning were also reported
as inefficiencies, including planning the patient pathway,
study monitoring and end-of-study planning:
Ramifications of poor planning at grant application
stage can result in drug supply issues, increased costs
or interruptions to IMP [investigational medicinal
product] supply, changes to eCRF [electronic case
report form] system after study start,
under-recruitment, etc.
Insufficient resource allocated to trial management or
marketing of the trial.
Discussion
It is estimated that 85% of research is wasted [3]. Fac-
tors contributing to research waste include conducting
studies that address questions of low importance to
patients and clinicians [4], that are designed without
reference to a systematic review of the evidence [4],
that fail to take adequate steps to reduce bias [5], and
that fail to report, or that inadequately report, their
results [6]. Improving the efficiency of trial conduct is
clearly an important strategy for reducing such waste
[1, 7]. Respondents to our survey represented a wide
range of roles and CTUs, although the response rate
was lower than expected (owing to a problem with
the email distribution list, subsequently corrected but
not in time for our response rate). The top reported
inefficiencies present no surprises: securing necessary
approvals and permission [8–10], poor recruitment
[11, 12] and data management [13] are all well recog-
nised as challenges to efficient trial conduct. Many of
the other issues identified relate to project planning,
such as doing appropriate pilot and feasibility assess-
ment, and selecting and maintaining good sites (good
at both recruitment and data collection), setting real-
istic recruitment targets and developing high-quality
documents and data collection tools. This emphasises
the importance of having sufficient time and expertise
in the early planning of a trial [13, 14], and offers
insight into a range of problems facing units
conducting multicentre trials. In view of the import-
ance of early planning for efficient trial conduct, it
would be useful to have early input, ideally from the
stage of preparing the grant application, from an ex-
perienced trial manager.
Several respondents noted the potential for recent
improvements in the process of securing research ethics
approval for multicentre studies (https://www.myresearch
project.org.uk/SignIn.aspx) and for obtaining local health
service approval at each site (http://www.ukcrc.org/regula-
tion-governance/streamlining-rd-permissions/national-
systems-for-rd-permissions/) to improve efficiency and re-
duce delays. Nevertheless, gaining approvals remained the
top reported inefficiency. In England, in 2016, the Health
Research Authority completed the introduction of a new
process called Health Research Authority Approval, which
streamlines within a single process the assessment of gov-
ernance and legal compliance (by dedicated Health Re-
search Authority staff ), with review by an independent
research ethics committee (http://www.hra.nhs.uk/about-
the-hra/our-plans-and-projects/assessment-approval/).
This appears to have reduced time to approval, but merits
evaluation to assess impact on overall efficiency. Contract
negotiations are another issue often outside the direct in-
fluence of an individual unit or research team. Similarly
beyond direct control by the unit, working with external
suppliers such as pharmaceutical companies and issues
around the supply of investigational medicinal product
were reported as inefficiencies by a few respondents.
Clearly, these are only issues for units that conduct clinical
trials of investigational medicinal products, which not all
do, as some only conduct trials of complex interventions
or medical devices.
Meeting recruitment targets is clearly a key challenge
for all trials. Responses in this survey indicate the wide
range of factors that can contribute to poor recruitment,
but also offer some insight into their potential solutions.
For example, recruitment targets should be realistic not
only for the study overall but also for individual sites.
Realistic targets for sites should be based on information
from those sites, which means collecting appropriate
data on the target population and assessing the patient
pathway. Meeting recruitment targets also depends on
selecting the right sites; hence, making better-
informed decisions about site selection, checking for
competing trials at sites, and strong engagement by
the local investigators will all improve efficiency in
recruitment. Using simple questionnaires to gather
relevant information from potential sites may improve
selection of sites. Prompt recognition of problems with
recruitment will facilitate rapid remedial action. Lack of en-
gagement from the study’s chief investigator, and poor com-
munication between the chief investigator and the project
team, were also noted as contributing to inefficiency.
Recruitment and training of staff were reported as
issues in inefficiency of trial conduct. For some
responses it was unclear whether the problem was
recruitment at the trials unit or at sites. However, it was
clear that delays in recruiting appropriate staff to work
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on the project once the grant was awarded could be a
major problem. Delays at this early stage can have
considerable impact throughout the study, as delays may
be cumulative and once a study falls behind target it can
be difficult to catch up.
Since our survey was conducted, several factors may
have contributed to potential improvement in efficient
trial conduct. As discussed, the approval process has
been changed and streamlined. The importance of meth-
odological research to increase our knowledge about
how to improve the efficiency and quality of trial con-
duct, in particular how to improve strategies for trial
management, is now more widely recognised. Initiatives
to raise awareness of and to facilitate such research in-
clude the SWAT (study within a trial) programme [15]
and Trial Forge, which aims to aims to increase the
evidence base for trial decision making [2]. The biennial
International Clinical Trials Methodology Conference
hosted by the Network of Hubs for Trials Methodology
Research has become well established, and provides a
forum for those interested in improving efficient trial
conduct to network, share experiences and present their
research.
Our survey addressed inefficiencies in the conduct of
individual trials, which contribute to waste in research
[7]. There are also broader issues with inefficiencies in
trial conduct that contribute to research waste, however
[16], for example how studies are selected for funding
[4], inaccessibility of full information about published
studies [17] and failure to report about half of all clinical
trials [3] (http://www.alltrials.net/). Advocacy for trans-
parency in clinical trials is accelerating, and is supported
by hundreds of institutions, including the UKCRC
registered CTUs network (http://c.ymcdn.com/sites/
www.ukcrc-ctu.org.uk/resource/resmgr/ukcrc_response
_eu_regs_summa.pdf ).
Conclusions
Recommendations for improving the efficiency of trial
conduct for multicentre trials include:
 Applying leverage for further reducing unnecessary
bureaucracy in approvals and contracting
 Improving training for site staff, for example by
developing ways for CTUs to share knowledge
about sites and work together to provide site
training
 Improving the working relationships between chief
investigators and CTUs, for example by developing
guidance on their respective roles and
responsibilities, including the importance of realistic
recruitment targets and feasibility for efficient
planning and conduct
 Sharing good practice across units and developing
training across the network of units
 Encouraging funders to release sufficient funding to
allow prompt recruitment of trial staff
 As we need better information about how to
improve efficient trial conduct, CTUs should
encourage research whenever possible to improve
our knowledge about how to improve the efficiency
and quality of trial conduct
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